Cocrystal Pharma, Inc. (COCP) intrinsic value & 10-year financials
Cocrystal Pharma, Inc. (COCP) has a Graham intrinsic value of $87.58 per share. At $1.02 on Oct 17, 2026, the stock trades 99% below that value.
- Graham intrinsic value
- $87.58
- Share price (Oct 17, 2026)
- $1.02
- Price vs Graham value
- 99% below
- Market cap
- $11.5M
- Revenue (FY2025)
- —
- Revenue growth (10-yr CAGR)
- -69.3%
- ROIC (10-yr avg)
- -396.1%
- Free cash flow (FY2025)
- -$8.2M
COCP 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$8.8M | -$0.78 | -$8.2M | — | -1073.7% |
| FY2024 | — | -$17.5M | -$1.72 | -$16.5M | — | -1245.0% |
| FY2023 | — | -$18.0M | -$1.87 | -$14.8M | — | -888.3% |
| FY2022 | — | -$38.8M | -$4.77 | -$21.5M | — | -360.5% |
| FY2021 | — | -$14.2M | — | -$12.8M | — | -72.7% |
| FY2020 | $2.0M | -$9.6M | — | -$10.1M | -476.0% | -49.9% |
| FY2019 | $6.6M | -$48.2M | — | -$1.7M | -737.4% | -115.9% |
| FY2018 | — | -$49.0M | — | -$8.3M | — | -76.7% |
| FY2017 | — | -$613.0K | -$0.03 | -$6.9M | — | -4.0% |
| FY2016 | — | -$74.9M | -$0.11 | -$14.7M | — | -74.3% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Cocrystal Pharma, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Cocrystal Pharma, Inc. has historically struggled to out-earn its cost of capital, averaging just -42.9% ROIC.
Over the decade, Cocrystal Pharma, Inc. shows that management has aggressively returned capital to shareholders by retiring 98.4% of outstanding shares.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Cocrystal Pharma, Inc. is modeled at -69.3% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $87.58 per share.